New research presented at the 2025 EULAR congress in Barcelona suggests that achieving serum urate targets within 1 year of treatment initiation in patients with gout may significantly reduce major cardiovascular events. The study evaluated outcomes in more than 116,000 patients and found that patients who achieved target serum urate levels demonstrated a higher 5-year MACE-free survival rate and a lower risk of MACE compared with those who did not reach the target levels. In addition, two investigational URAT1 inhibitors demonstrated superior efficacy and favorable safety profiles compared with standard allopurinol therapy, supporting their potential as treatment options for gout patients.

Source: EULAR Press Release